This is the authors' abstract. We don't add key points for this paper.
BRAF inhibitors, vemurafenib and dabrafenib, are the mainstay of treatmentfor BRAF-mutant metastatic melanoma. Cutaneous toxicities are themostfrequent adverse effects, particularly hyperkeratosis (6% to 51% with vemurafenib), as well as cutaneous squamous cell carcinoma and keratoacanthoma (4.3% to 31% with vemurafenib, 6% to 11% with dabrafenib).1 Photosensitivity can occur in 52% of patients treated with vemurafenib. Radiation therapy plays an important role in the treatment of patients with metastatic melanoma. In this report, we describe five patients who experienced unanticipated increased in-field skin toxicity while undergoing radiotherapy with the concomitant use of BRAF inhibitors.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Pulvirenti et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: